| 58 | 0 | 27 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 应用2019版Beers标准和中国老年人潜在不适当用药判断标准(2017年版)(中国标准)进行老年住院患者潜在不适当用药(PIM)分析。方法 选择2020年1月—6月于山东第一医科大学附属省立医院老年科住院的年龄≥65岁患者191例，基于2019版Beers标准和中国标准进行PIM分析，并应用χ2检验分别比较两个标准下不同指标(年龄、性别、疾病数量、药物数量、肾功能)PIM发生率。结果 根据Beers标准和中国标准，PIM的发生率分别为72.25%(138/191)和60.73%(116/191),PIM首位分别为质子泵抑制剂和氯吡格雷。根据Beers标准和中国标准，使用1～4、5～9、≥10种药物的老年住院患者PIM发生率比较差异均有统计学意义(P均<0.05)。根据中国标准，肾功能正常、异常患者的PIM发生率比较差异有统计学意义(P<0.05)。结论 无论是基于2019版Beers标准还是中国标准，老年住院患者PIM发生率均高，药物数量增加和肾功能异常者更容易发生PIM。
Abstract：Objective To analyze potentially inappropriate medication(PIM) in elderly inpatients using the 2019 Beers Criteria and the Chinese Criteria of Potentially Inappropriate Medication for Older Adults(2017 edition)(Chinese Criteria). Methods A total of 191 inpatients aged ≥65 years admitted to the Department of Geriatrics of Shandong Provincial Hospital Affiliated to Shandong First Medical University from January to June 2020 were selected. PIM analysis was performed based on the 2019 Beers Criteria and Chinese Criteria. The χ2 test was used to compare the incidence rates of PIM by two criteria across different indicators(age, sex, number of diseases, number of medications, renal function). Results According to the Beers Criteria and Chinese Criteria, the incidence rates of PIM were 72. 25%(138/191) and 60. 73%(116/191), respectively. The most frequent PIM were proton pump inhibitors(based on Beers Criteria) and clopidogrel(based on Chinese Criteria). Difference of PIM incidence was found according to both Beers Criteria and Chinese Criteria among elderly inpatients taking 1-4, 5-9, and ≥10 medications(all P<0. 05). According to the Chinese Criteria, difference in PIM incidence was observed between patients with normal and abnormal renal function(P<0. 05). Conclusions Based on the 2019 Beers Criteria and Chinese Criteria, the incidence of PIM among elderly inpatients is very high. Elderly patients taking more medications and those with abnormal renal function are more prone to PIM.
[1] SKOU S T, MAIR F S, FORTIN M, et al. Multimorbidity[J].Nat Rev Dis Primers, 2022,8(1):48.
[2] DOVJAK P. Polypharmacy in elderly people[J]. Wien Med Wochenschr, 2022,172(5-6):109-113.
[3] WISE J. Polypharmacy:a necessary evil[J]. BMJ, 2013,347:f7033.
[4] By the 2019 American Geriatrics Society Beers Criteria?Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria?for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc, 2019,67(4):674-694.
[5] GALLAGHER P, RYAN C, BYRNE S, et al. STOPP(Screening Tool of Older Person's Prescriptions)and START(Screening Tool to Alert doctors to Right Treatment). Consensus validation[J]. Int J Clin Pharmacol Ther, 2008,46(2):72-83.
[6] O'MAHONY D, O'SULLIVAN D, BYRNE S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people:version 2[J]. Age Ageing, 2015,44(2):213-218.
[7]中国老年保健医学研究会老年合理用药分会，中华医学会老年医学分会，中国药学会老年药学专业委员会，等.中国老年人潜在不适当用药判断标准（2017年版）[J].药物不良反应杂志，2018,20(1):2-8.
[8]刘玉龙，孙燕，方栒，等. 317例老年住院患者潜在不适当用药情况分析[J].中国药业，2019,28(19):85-89.
[9] BAI Y, WANG J, LI G, et al. Evaluation of potentially inappropriate medications in older patients admitted to the cardiac intensive care unit according to the 2019 Beers criteria, STOPP criteria version 2 and Chinese criteria[J]. J Clin Pharm Ther, 2022,47(12):1994-2007.
[10] TAO L, QU X, GAO H, et al. Polypharmacy and potentially inappropriate medications among elderly patients in the geriatric department at a single-center in China:a retrospective cross-sectional study[J]. Medicine(Baltimore), 2021,100(42):e27494.
[11] SHANG Y S, ZHONG P Y, MA Y, et al. Efficacy and safety of proton pump inhibitors in patients with coronary artery diseases receiving oral antiplatelet agents and/or anticoagulants:a systematic review and meta-analysis[J]. J Cardiovasc Pharmacol,2022,80(1):1-12.
[12] PORTER B, ARTHUR A, SAVVA G M. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study[J]. BMJ Open, 2019,9(5):e026171.
[13] ADOMAKO E A, SAMBANDAM K K. Challenges in diuretic therapy:a case-based discussion[J]. Am J Med Sci, 2022,364(4):386-393.
[14] PATEL D, STEINBERG J, PATEL P. Insomnia in the elderly:a review[J]. J Clin Sleep Med, 2018,14(6):1017-1024.
[15] GILLETTE M, MORNEAU K, HOANG V, et al. Antiplatelet management for coronary heart disease:advances and challenges[J]. Curr Atheroscler Rep, 2016,18(6):35.
[16] Timeline:Insulin and diabetes[J]. Cell Metab, 2021,33(4):846.
[17] ZHOU D, CHEN Z, TIAN F. Deprescribing interventions for older patients:a systematic review and meta-analysis[J]. J Am Med Dir Assoc, 2023,24(11):1718-1725.
[18] RODRIGUES D A, PLáCIDO A I, MATEOS-CAMPOS R, et al.Effectiveness of interventions to reduce potentially inappropriate medication in older patients:a systematic review[J]. Front Pharmacol, 2021,12:777655.
[19]许伟，彭婕.肾功能不全患者不合理用药医嘱分析[J].药学与临床研究，2021,29(1):50-52.
[20]龚皓鸣，吴建博，沈杰，等.华东医院70岁以上老年住院患者潜在不适当用药（PIM）情况及其影响因素[J].复旦学报（医学版），2019,46(2):205-211.
[21] SECORA A, ALEXANDER G C, BALLEW S H, et al. Kidney function, polypharmacy, and potentially inappropriate medication use in a community-based cohort of older adults[J]. Drugs Aging, 2018,35(8):735-750.
基本信息:
DOI：
中图分类号:R969.3
引用信息:
[1]万苗苗,王建春,张峰,等.基于Beers标准和中国标准的老年住院患者潜在不适当用药分析[J].老年医学研究,2025,6(04):1-4.
基金信息:
国家重点研发项目(2020YFC2008900,老年常见临床问题防控技术综合示范研究;2020YFC2008902,老年合理用药评价干预方案与技术措施)